Form 8-K - Current report:
SEC Accession No. 0001999371-25-007625
Filing Date
2025-06-11
Accepted
2025-06-11 17:24:30
Documents
19
Period of Report
2025-06-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT tnxp-8k.htm   iXBRL 8-K 47750
2 SALES AGREEMENT ex1-01.htm EX-1.01 276248
3 OPINION OF BROWNSTEIN HYATT FARBER SCHRECK, LLP ex5-01.htm EX-5.01 17294
4 OPINION OF BROWNSTEIN HYATT FARBER SCHRECK, LLP ex5-02.htm EX-5.02 14724
5 PURCHASE AGREEMENT ex10-01.htm EX-10.1 274925
6 REGISTRATION RIGHTS AGREEMENT ex10-02.htm EX-10.02 108291
10 GRAPHIC ex501001.jpg GRAPHIC 11909
11 GRAPHIC ex502001.jpg GRAPHIC 8452
  Complete submission text file 0001999371-25-007625.txt   1093207

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE tnxp-20250611.xsd EX-101.SCH 3023
8 XBRL LABEL FILE tnxp-20250611_lab.xml EX-101.LAB 34239
9 XBRL PRESENTATION FILE tnxp-20250611_pre.xml EX-101.PRE 24170
21 EXTRACTED XBRL INSTANCE DOCUMENT tnxp-8k_htm.xml XML 3543
Mailing Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928
Business Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928 212-980-9155
Tonix Pharmaceuticals Holding Corp. (Filer) CIK: 0001430306 (see all company filings)

EIN.: 261434750 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36019 | Film No.: 251040955
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)